MedTrace Logo

Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes

NCT01154647 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2010-07-01

No results posted yet for this study

Summary

Both patients with peripheral structural pathologies, like rheumatoid arthritis (RA)-patients, or patients with central sensitivity syndromes (CSS) suffer chronic pain. CSS are characterized by an increased responsiveness of central pain neurons. An impaired endogenous pain inhibition is already demonstrated in CSS. In the present study the investigators want to evaluate the efficacy of pain inhibition in response to physical stressors and whether the efficacy is opioid-mediated in two chronic pain populations (RA \& CCS) compared to controls.

Therefore a triple-blinded randomized controlled trial (RCT) with cross-over design will be performed. The efficacy of wind-up of pain and spatial summation of pain is evaluated before and after a submaximal exercise, while the experimental group receives a selective serotonin reuptake inhibitor. Participants are 20 RA-patients and 20 CSS-patients, more specific patients with fibromyalgia and chronic fatigue syndrome, and 30 healthy controls. This way, the investigators analyze how pain inhibition reacts on different types of physical stressors in different pain patients and if pain inhibition is opioid-mediated.

Conditions

  • Fatigue Syndrome, Chronic
  • Fibromyalgia
  • Arthritis, Rheumatoid

Interventions

DRUG

citalopram

intravenous

DRUG

1 ml 0.9 % NaCl

intravenous

Sponsors & Collaborators

  • Research Foundation Flanders

    collaborator OTHER

  • Universiteit Antwerpen

    collaborator OTHER

  • University Hospital, Antwerp

    collaborator OTHER

  • Artesis University College, Antwerp

    collaborator OTHER

  • Vrije Universiteit Brussel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154647 on ClinicalTrials.gov